PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
-0.49%
Cost reduction while RVPH shows 0.00% growth. Joel Greenblatt would examine competitive advantage.
0.49%
Growth of 0.49% while RVPH shows flat gross profit. Bruce Berkowitz would examine quality advantage.
No Data
No Data available this quarter, please select a different quarter.
-36.64%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
-70.64%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-54.90%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-54.90%
Both companies reducing total costs. Martin Whitman would check industry trends.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
D&A reduction while RVPH shows 0.00% growth. Joel Greenblatt would examine efficiency.
54.90%
EBITDA growth exceeding 1.5x RVPH's 5.85%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
54.90%
Operating income growth exceeding 1.5x RVPH's 7.11%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
-10.71%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
56.85%
Pre-tax income growth exceeding 1.5x RVPH's 5.94%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
56.85%
Net income growth exceeding 1.5x RVPH's 5.90%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
56.86%
EPS growth exceeding 1.5x RVPH's 7.69%. David Dodd would verify competitive advantages.
56.86%
Diluted EPS growth exceeding 1.5x RVPH's 7.69%. David Dodd would verify competitive advantages.
-0.00%
Share count reduction while RVPH shows 2.47% change. Joel Greenblatt would examine strategy.
-0.00%
Diluted share reduction while RVPH shows 2.47% change. Joel Greenblatt would examine strategy.